GSK plc
GSK
Jodie situation report
GSK plc's move is being confirmed by its market group.
GSK accounts for 4.1% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for GSK could be timestamped inside the aligned 5-minute window.
8 of 15 members in Biopharmaceuticals and Care are active. No disclosed relationship network is available for this name; the confirmation read above is market-derived.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABBV begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind GSK
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
GSK is currently a Early Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.